Treatment trials in progressive MS—current challenges and future directions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment trials in progressive MS—current challenges and future directions

Published:2013-07-30 Issue:9 Volume:9 Page:496-503
ISSN:1759-4758
Container-title:Nature Reviews Neurology
language:en
Short-container-title:Nat Rev Neurol

Author:

Koch Marcus W.,Cutter Gary,Stys Peter K.,Yong V. Wee,Metz Luanne M.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Link

http://www.nature.com/articles/nrneurol.2013.148.pdf

Reference87 articles.

1. Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).

2. Miller, D. H. & Leary, S. M. Primary-progressive multiple sclerosis. Lancet Neurol. 6, 903–912 (2007).

3. Rovaris, M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5, 343–354 (2006).

4. [No authors listed]. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498–1504 (1998).

5. [No authors listed]. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon β-1b in secondary progressive MS. Lancet 352, 1491–1497 (1998).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset;Journal of Neurology;2022-05-16

2. Space Renaissance and Neurodegeneration;Spaceflight and the Central Nervous System;2022

3. Efficacy and safety of N-acetyl-l-leucine in Niemann–Pick disease type C;Journal of Neurology;2021-08-13

4. Repurposing Domperidone in Secondary Progressive Multiple Sclerosis;Neurology;2021-03-23

5. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set;Multiple Sclerosis Journal;2021-01-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3